Gilead buys nearly 50% equity interest in cancer immunotherapy-focused Pionyr for $275M
The biotech company will have the exclusive option to buy the remainder of the company, while Pionyr's shareholders will be entitled to up to nearly $1.5 billion in option exercise fees and milestone payments.